11 Best Guru Stocks to Buy According to Wall Street Analysts

3. Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Number of Hedge Fund Holders: 40

Average Upside Potential: 132.55%

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a New Jersey-based biotech company dedicated to developing innovative treatments for rare diseases. It offers oral therapy for adults with Fabry disease, and a unique two-part treatment designed for adults with late-onset Pompe disease. FOLD ranks 3rd on our list of the best Guru stocks. On February 19, BofA reiterated a Buy rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) but cut the price target from $15 to $14. BofA analysts are confident in Galafold’s sustained success and Pombiliti+Opfolda’s potential, noting that the company is well-positioned for future growth.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) concluded last year with $528.3 million in full-year revenue, reflecting a 33% growth at constant exchange rates. The fourth quarter revenue came in at $149.7 million, up 30%. The company expects sales to grow another 17-24% in 2025 and is aiming to cross $1 billion in total revenue by 2028. While it posted a $56.1 million net loss for the year, it is a big improvement from 2023. Amicus is on track to report positive net income in the second half of 2025. Cash and investments held steady at around $250 million by the end of 2024.

According to Insider Monkey’s fourth quarter database, 40 hedge funds were bullish on Amicus Therapeutics, Inc. (NASDAQ:FOLD), compared to 38 funds in the prior quarter. Joseph Edelman’s Perceptive Advisors was the leading stakeholder of the company, with 24.2 million shares worth $228.4 million.